David M Hyman

List of Publications by Year
in descending order

129 papers	25,649 citations	19608 61 h-index	12910 131 g-index
135 all docs	135 docs citations	135 times ranked	31358 citing authors

#	Article	IF	Citations
1	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine, 2017, 23, 703-713.	15.2	2,473
2	Efficacy of Larotrectinib inTRKFusionâ€“Positive Cancers in Adults and Children. New England Journal of Medicine, 2018, 378, 731-739.	13.9	2,036
3	Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. New England Journal of Medicine, 2015, 373, 726-736.	13.9	1,483
4	A view on drug resistance in cancer. Nature, 2019, 575, 299-309.	13.7	1,391
5	OncoKB: A Precision Oncology Knowledge Base. JCO Precision Oncology, 2017, 2017, 1-16.	1.5	1,266
6	Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science, 2018, 359, 582-587.	6.0	834
7	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell, 2018, 34, 427-438.e6.	7.7	633
8	Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncology, The, 2020, 21, 531-540.	5.1	608
9	Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. Cancer Cell, 2018, 33, 125-136.e3.	7.7	589
10	Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. Cell Stem Cell, 2017, 21, 374-382.e4.	5.2	578
11	HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature, 2018, 554, 189-194.	13.7	572
12	Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. Cancer Discovery, 2017, 7, 596-609.	7.7	490
13	High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nature Medicine, 2019, 25, 1928-1937.	15.2	485
14	Genome doubling shapes the evolution and prognosis of advanced cancers. Nature Genetics, 2018, 50, 1189-1195.	9.4	411
15	Implementing Genome-Driven Oncology. Cell, 2017, 168, 584-599.	13.5	405
16	Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies. Clinical Cancer Research, 2019, 25, 2116-2126.	3.2	390
17	Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. Journal of Clinical Oncology, 2018, 36, 2532-2537.	0.8	381
18	Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncology, The, 2019, 20, 711-718.	5.1	381

#	Article	IF	Citations
19	NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Modern Pathology, 2020, 33, 38-46.	2.9	373
20	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer Discovery, 2016, 6, 154-165.	7.7	372
21	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nature Genetics, 2020, 52, 1219-1226.	9.4	367
22	Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. JAMA - Journal of the American Medical Association, 2017, 318, 825.	3.8	366
23	Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions. American Journal of Surgical Pathology, 2017, 41, 1547-1551.	2.1	353
24	A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusionâ€“Positive Solid Tumors. Cancer Discovery, 2017, 7, 963-972.	7.7	331
25	Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations. Cancer Discovery, 2018, 8, 1227-1236.	7.7	321
26	Small molecules, big impact: 20 years of targeted therapy in oncology. Lancet, The, 2020, 395, 1078-1088.	6.3	302
27	Tumour lineage shapes BRCA-mediated phenotypes. Nature, 2019, 571, 576-579.	13.7	295
28	High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden. Clinical Cancer Research, 2019, 25, 4712-4722.	3.2	292
29	Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. JCO Precision Oncology, 2017, 2017, 1-16.	1.5	286
30	Accelerating Discovery of Functional Mutant Alleles in Cancer. Cancer Discovery, 2018, 8, 174-183.	7.7	275
31	Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. JAMA Oncology, 2016, 2, 104.	3.4	270
32	BRAF Inhibition in BRAF^{V600}-Mutant Gliomas: Results From the VE-BASKET Study. Journal of Clinical Oncology, 2018, 36, 3477-3484.	0.8	247
33	AKT Inhibition in Solid Tumors With AKT1 Mutations. Journal of Clinical Oncology, 2017, 35, 2251-2259.	0.8	240
34	DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma. Clinical Cancer Research, 2017, 23, 3610-3618.	3.2	225
35	Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature, 2019, 567, 521-524.	13.7	222
36	Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer. Clinical Cancer Research, 2017, 23, 6708-6720.	3.2	194

#	Article	IF	Citations
37	The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers. JAMA Oncology, 2017, 3, 244.	3.4	191
38	NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma. American Journal of Surgical Pathology, 2018, 42, 791-798.	2.1	182
39	BRAF Mutation is associated with early stage disease and improved outcome in patients with lowâ€grade serous ovarian cancer. Cancer, 2013, 119, 548-554.	2.0	169
40	Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. Clinical Cancer Research, 2017, 23, 6094-6100.	3.2	161
41	HER2-Mediated Internalization of Cytotoxic Agents inERBB2Amplified or Mutant Lung Cancers. Cancer Discovery, 2020, 10, 674-687.	7.7	149
42	Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using ⁸⁹Zr-Trastuzumab PET/CT. Journal of Nuclear Medicine, 2016, 57, 1523-1528.	2.8	146
43	Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Nature Medicine, 2019, 25, 1422-1427.	15.2	144
44	Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors. JAMA Oncology, 2018, 4, 1589.	3.4	139
45	Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition. Cancer Discovery, 2018, 8, 1540-1547.	7.7	138
46	Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. Drug Discovery Today, 2015, 20, 1422-1428.	3.2	136
47	Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. JAMA Oncology, 2018, 4, 1228.	3.4	132
48	RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling. Nature Medicine, 2019, 25, 284-291.	15.2	125
49	Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nature Medicine, 2019, 25, 1839-1842.	15.2	122
50	Prospective Blinded Study of BRAFV600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders. Cancer Discovery, 2015, 5, 64-71.	7.7	115
51	Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions. Cancer Research, 2019, 79, 1047-1053.	0.4	112
52	Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. Clinical Cancer Research, 2019, 25, 5537-5547.	3.2	107
53	TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations. Clinical Cancer Research, 2020, 26, 1624-1632.	3.2	103
54	Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer. Clinical Cancer Research, 2018, 24, 5939-5947.	3.2	100

#	Article	IF	Citations
55	Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status. Journal of Molecular Diagnostics, 2017, 19, 244-254.	1.2	96
56	Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers. Cancer Discovery, 2020, 10, 657-663.	7.7	93
57	Mechanisms of Resistance to Noncovalent Brutonâ€™s Tyrosine Kinase Inhibitors. New England Journal of Medicine, 2022, 386, 735-743.	13.9	87
58	An Acquired HER2â€ˆT798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutantâ€“Driven Breast Cancer. Cancer Discovery, 2017, 7, 575-585.	7.7	85
59	Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer. Cancer Discovery, 2020, 10, 198-213.	7.7	83
60	Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer. Cancer Cell, 2018, 34, 852-862.e4.	7.7	73
61	Improved survival for BRCA2â€associated serous ovarian cancer compared with both BRCAâ€negative and BRCA1â€associated serous ovarian cancer. Cancer, 2012, 118, 3703-3709.	2.0	72
62	A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer. Clinical Cancer Research, 2018, 24, 3253-3262.	3.2	71
63	Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care. JAMA Oncology, 2020, 6, 84.	3.4	66
64	Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology. Annual Review of Medicine, 2018, 69, 319-331.	5.0	61
65	Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies. Oncotarget, 2016, 7, 85430-85436.	0.8	60
66	Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing. Clinical Cancer Research, 2020, 26, 3881-3888.	3.2	59
67	Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. Cancer Research, 2017, 77, 6513-6523.	0.4	58
68	Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients withAKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer. Clinical Cancer Research, 2020, 26, 3947-3957.	3.2	54
69	Placental site trophoblastic tumor: Analysis of presentation, treatment, and outcome. Gynecologic Oncology, 2013, 129, 58-62.	0.6	53
70	Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). Science Signaling, 2018, 11, .	1.6	53
71	OncoTree: A Cancer Classification System for Precision Oncology. JCO Clinical Cancer Informatics, 2021, 5, 221-230.	1.0	51
72	Nomogram to Predict Cycle-One Serious Drug-Related Toxicity in Phase I Oncology Trials. Journal of Clinical Oncology, 2014, 32, 519-526.	0.8	47

#	Article	IF	Citations
73	First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors. Clinical Cancer Research, 2019, 25, 5458-5465.	3.2	47
74	The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers. Nature Communications, 2022, 13, 1450.	5.8	47
75	Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF. Molecular Cancer Research, 2016, 14, 296-301.	1.5	46
76	Disseminated Intravascular Coagulation with Excessive Fibrinolysis in Prostate Cancer: A Case Series and Review of the Literature. Oncology, 2011, 81, 119-125.	0.9	45
77	The role of systemic chemotherapy in the management of granulosa cell tumors. Gynecologic Oncology, 2015, 136, 505-511.	0.6	45
78	Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies. Journal of Clinical Investigation, 2018, 128, 3819-3825.	3.9	45
79	The context-specific role of germline pathogenicity in tumorigenesis. Nature Genetics, 2021, 53, 1577-1585.	9.4	44
80	Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion. PLoS ONE, 2015, 10, e0126633.	1.1	41
81	Single-agent dabrafenib for BRAF ^{V600E} -mutated histiocytosis. Haematologica, 2018, 103, e177-e180.	1.7	40
82	Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted ⁸⁹Zr-Pertuzumab PET/CT. Radiology, 2020, 296, 370-378.	3.6	40
83	Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway. Cancer, 2020, 126, 1274-1282.	2.0	37
84	Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer. Gynecologic Oncology, 2020, 156, 194-202.	0.6	35
85	Clinical tumour sequencing for precision oncology: time for a universal strategy. Nature Reviews Cancer, 2018, 18, 527-528.	12.8	34
86	TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors. Cancer Discovery, 2021, 11, 126-141.	7.7	34
87	Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade. Gynecologic Oncology, 2019, 152, 251-258.	0.6	33
88	Neurologic and oncologic features of Erdheimâ€“Chester disease: a 30-patient series. Neuro-Oncology, 2020, 22, 979-992.	0.6	31
89	Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma. Gynecologic Oncology, 2012, 126, 224-228.	0.6	29
90	Discovery through clinical sequencing in oncology. Nature Cancer, 2020, 1, 774-783.	5.7	29

#	Article	IF	Citations
91	Automated eligibility screening and monitoring for genotype-driven precision oncology trials. Journal of the American Medical Informatics Association: JAMIA, 2016, 23, 777-781.	2.2	27
92	BRAF V600E Mutation and Clonal Evolution in a Patient With Relapsed Refractory Myeloma With Plasmablastic Differentiation. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, e65-e68.	0.2	22
93	Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients withPIK3CA-Mutant Cancers. Clinical Cancer Research, 2021, 27, 447-459.	3.2	22
94	Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21Âdays or q28Âdays) for patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2015, 75, 747-755.	1.1	21
95	Toward a More Precise Future for Oncology. Cancer Cell, 2020, 37, 431-442.	7.7	21
96	Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring BRAF^{V600} Mutations: A Cohort of the Histology-Independent VE-BASKET Study. JCO Precision Oncology, 2018, 2, 1-9.	1.5	20
97	Diffuse reduction of cerebral grey matter volumes in Erdheim-Chester disease. Orphanet Journal of Rare Diseases, 2016, 11, 109.	1.2	19
98	Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer. Annals of Surgical Oncology, 2018, 25, 2027-2033.	0.7	19
99	Next-Generation Sequencingâ€“Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer. Journal of Molecular Diagnostics, 2019, 21, 307-317.	1.2	19
100	The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma. Clinical Cancer Research, 2017, 23, 4119-4126.	3.2	17
101	A scale for patient-reported symptom assessment for patients with Erdheim-Chester disease. Blood Advances, 2019, 3, 934-938.	2.5	17
102	Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer family. Breast Cancer Research and Treatment, 2016, 160, 447-456.	1.1	16
103	Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities. Clinical Cancer Research, 2016, 22, 553-559.	3.2	16
104	Precision oncology: Charting a path forward to broader deployment of genomic profiling. PLoS Medicine, 2017, 14, e1002242.	3.9	16
105	Larotrectinib Demonstrates CNS Efficacy in TRK Fusion-Positive Solid Tumors. JCO Precision Oncology, 2019, 3, 1-5.	1.5	15
106	Tumor Genetic Screening Programs: A Call to Action. Journal of Clinical Oncology, 2015, 33, 2725-2726.	0.8	14
107	Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials. Oncotarget, 2015, 6, 19316-19327.	0.8	13
108	Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations. JCO Precision Oncology, 2019, 3, 1-13.	1.5	11

#	Article	IF	Citations
109	Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel AKT1 Fusionâ€“Driven Cancer. Cancer Discovery, 2019, 9, 605-616.	7.7	11
110	Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers. Gynecologic Oncology, 2011, 123, 196-199.	0.6	10
111	Beyond the doseâ€limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program. Cancer, 2016, 122, 1228-1237.	2.0	10
112	A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel. Investigational New Drugs, 2017, 35, 742-750.	1.2	10
113	Activating Mutations in CSF1R and Additional Receptor Tyrosine Kinases in Sporadic and Familial Histiocytic Neoplasms. Blood, 2018, 132, 49-49.	0.6	10
114	AKT mutant allele-specific activation dictates pharmacologic sensitivities. Nature Communications, 2022, 13, 2111.	5.8	10
115	Use, Safety, and Efficacy of Single-Patient Use of the US Food and Drug Administration Expanded Access Program. JAMA Oncology, 2019, 5, 570.	3.4	9
116	Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib. Current Problems in Cancer, 2021, 45, 100734.	1.0	9
117	MEK Inhibitor-Associated Central Retinal Vein Occlusion Associated with Hyperhomocysteinemia and MTHFR Variants. Ocular Oncology and Pathology, 2020, 6, 159-163.	0.5	8
118	Understanding Inherited Risk in Unselected Newly Diagnosed Patients With Endometrial Cancer. JCO Precision Oncology, 2019, 3, 1-15.	1.5	7
119	Comprehensive Genomic Analysis of Metastatic Nonâ€“Clear-Cell Renal Cell Carcinoma to Identify Therapeutic Targets. JCO Precision Oncology, 2019, 3, 1-18.	1.5	7
120	Genome-Driven Paradigm for the Development of Selective Fibroblast Growth Factor Receptor Inhibitors. Journal of Clinical Oncology, 2017, 35, 131-134.	0.8	6
121	Real-World Outcomes of an Automated Physician Support System for Genome-Driven Oncology. JCO Precision Oncology, 2019, 3, 1-13.	1.5	6
122	Clinical implications of drugâ€induced liver injury in earlyâ€phase oncology clinical trials. Cancer, 2020, 126, 4967-4974.	2.0	6
123	Natural History and Characteristics of ERBB2-mutated Hormone Receptorâ€“positive Metastatic Breast Cancer: A Multi-institutional Retrospective Caseâ€“control Study from AACR Project GENIE. Clinical Cancer Research, 2022, 28, 2118-2130.	3.2	3
124	Genomic Heterogeneity Underlies Mixed Response to Tropomyosin Receptor Kinase Inhibition in Recurrent Glioma. JCO Precision Oncology, 2018, 2, 1-6.	1.5	2
125	Reply to M. Voskoboynik et al. Journal of Clinical Oncology, 2014, 32, 3199-3200.	0.8	1
126	Primary debulking surgery for metastatic cervical adenocarcinoma: A case report. Gynecologic Oncology Reports, 2015, 14, 23-25.	0.3	1

#	Article	IF	Citations
127	Learning All That We Can From MyPathway. Journal of Clinical Oncology, 2018, 36, 2450-2451.	0.8	1
128	Measuring Toxicity in Phase I Clinical Trialsâ€"Letter. Clinical Cancer Research, 2016, 22, 1828-1828.	3.2	0
129	TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors. SSRN Electronic Journal, 0, , .	0.4	0